Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a compliance notice from Health Canada for its cancer biosimilar Bevqolva, a bevacizumab-based treatment used across multiple cancers. The development signals Health Canada’s confirmation of safety and efficacy, paving the way for broader access to potential cost-effective options for patients in Canada.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
